Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'
Portfolio Pulse from Avi Kapoor
Jim Cramer advises holding Palantir as it shows potential for growth, while warning about Travere Therapeutics' financial losses. Palantir is expected to report increased earnings, and Travere is anticipated to report a loss. Stanley Black & Decker is expected to maintain a positive outlook.
October 23, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Palantir Technologies is expected to report increased earnings, with analysts projecting 9 cents per share, up from 7 cents a year ago. Jim Cramer suggests holding the stock as it shows potential for growth.
Palantir is expected to report increased earnings, which is a positive indicator for the stock. Jim Cramer's advice to hold suggests confidence in its growth potential.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Stanley Black & Decker is expected to maintain a positive outlook, with a regular cash dividend approved and a new board member appointed.
The approval of a regular dividend and appointment of a new board member suggest stability, but no immediate impact on stock price is expected.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Travere Therapeutics is expected to report a quarterly loss of 66 cents per share, a significant drop from a year-ago profit. Jim Cramer warns about the company's financial losses.
The expected quarterly loss and Jim Cramer's warning indicate potential negative impact on Travere's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90